Drug details
Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn for injection)
type of Monoclonal Antibodies
Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) is a combination of Zaire ebolavirus glycoprotein-directed human monoclonal antibodies used to treat infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
This drug may have the following side effects:
- vomiting,
- fever,
- chills,
- low blood pressure (hypotension),
- fast heart rate,
- diarrhea, and
- fast, shallow breathing,
- low blood oxygen (hypoxia)